XBiotech pauses rheumatology program after Phase II study results

From GlobeNewswire: 2024-12-23 19:53:07

XBiotech halts clinical program for rheumatologic diseases due to challenges interpreting results from recent Phase II study on rheumatoid arthritis. Approximately 230 patients with moderate to severe rheumatoid arthritis participated in the study, testing XBiotech’s drug candidate, Natrunix, in combination with methotrexate. Although the study did not meet its primary endpoint on the ACR 20 scale after 12 weeks, further analysis is underway to understand the impact and guide potential future studies. XBiotech specializes in True Human™ antibody technology, with a focus on developing therapeutics from donors with natural immunity. For more information, visit www.xbiotech.com.

Please note that all forward-looking statements in this press release are subject to inherent risks and uncertainties, with potential variations from actual results. These risks and uncertainties are outlined in our SEC reports under the “Risk Factors” section. The forward-looking statements only apply as of the date of this press release, and we do not undertake to update them after this date. For further inquiries, contact Wenyi Wei at [email protected] or call 737-207-4600.



Read more at GlobeNewswire: XBiotech setzt Rheumatologieprogramm aus